Item 5.07. Submission of Matters to a Vote of Security Holders
On June 15, 2023, Acutus Medical, Inc. (the "Company") held its Annual Meeting
of Stockholders (the "Annual Meeting"). The Company's definitive proxy statement
for the Annual Meeting was filed with the U.S. Securities and Exchange
Commission (the "SEC") on April 27, 2023 and describes in detail both of the two
proposed voting matters (the "Proposals") submitted to the Company's
stockholders at the Annual Meeting. The final results for the votes cast with
respect to each Proposal are set forth below.
As of April 17, 2023, the record date of the Annual Meeting, there were
28,955,102 outstanding shares of the Company's common stock. At the Annual
Meeting, a quorum of 19,360,915 shares of the Company's common stock were
represented in person or by proxy.
Proposal 1
The stockholders elected each of David Bonita, MD and Jason Garland, as a Class
III director to hold office until the 2026 Annual Meeting of Stockholders, and
in each case until their respective successors are duly elected and qualified,
by the following vote:
Nominee Votes For Votes Withheld Broker Non-Votes
David Bonita, MD 7,533,710 2,151,944 9,675,261
Jason Garland 9,612,928 73,026 9,675,261
Proposal 2
The stockholders ratified the appointment of KPMG LLP as the Company's
independent registered public accounting firm for the fiscal year ending
December 31, 2023 by the following vote:
Votes For Votes Against Abstentions
9,211,539 100,281 49,095
No other items were presented for stockholder approval at the Annual Meeting.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
Exhibit
Number Description
104.0 Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ACUTUS MEDICAL, INC. 
